Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 29, 2024VirusesOpen Access

COVID-19 Vaccines: Where Did We Stand at the End of 2023?

View Full Paper
Ask AI
Bookmark
Share

Authors

KLKenneth LundströmBoston University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kenneth Lundström (2024) studied this question.

synapsesocial.com/papers/6a82bca71a33da52dd1c295ahttps://doi.org/10.3390/v16020203
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters2021 · 24 citations
  2. 2Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S2022 · 252 citations
  3. 3Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine2020 · 10,918 citations
  4. 4Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice2022 · 31 citations
  5. 5XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.12024 · 184 citations